[HTML][HTML] CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity

E Jacoby, SM Nguyen, TJ Fountaine, K Welp… - Nature …, 2016 - nature.com
E Jacoby, SM Nguyen, TJ Fountaine, K Welp, B Gryder, H Qin, Y Yang, CD Chien, AE Seif
Nature communications, 2016nature.com
Adoptive immunotherapy using chimeric antigen receptor (CAR) expressing T cells targeting
the CD19 B lineage receptor has demonstrated marked success in relapsed pre-B-cell acute
lymphoblastic leukaemia (ALL). Persisting CAR-T cells generate sustained pressure against
CD19 that may drive unique mechanisms of resistance. Pre-B ALL originates from a
committed pre-B cell or an earlier progenitor, with potential to reprogram into other
hematopoietic lineages. Here we report changes in lineage markers including myeloid …
Abstract
Adoptive immunotherapy using chimeric antigen receptor (CAR) expressing T cells targeting the CD19 B lineage receptor has demonstrated marked success in relapsed pre-B-cell acute lymphoblastic leukaemia (ALL). Persisting CAR-T cells generate sustained pressure against CD19 that may drive unique mechanisms of resistance. Pre-B ALL originates from a committed pre-B cell or an earlier progenitor, with potential to reprogram into other hematopoietic lineages. Here we report changes in lineage markers including myeloid conversion in patients following CD19 CAR therapy. Using murine ALL models we study the long-term effects of CD19 CAR-T cells and demonstrate partial or complete lineage switch as a consistent mechanism of CAR resistance depending on the underlying genetic oncogenic driver. Deletion of Pax5 or Ebf1 recapitulates lineage reprogramming occurring during CD19 CAR pressure. Our findings establish lineage switch as a mechanism of CAR resistance exposing inherent plasticity in genetic subtypes of pre-B-cell ALL.
nature.com